This Circulating Tumor Cells (CTCs) and free Circulating Nucleic Acids (FcNAs) report presents the findings from two new global studies that profiled 855 end-users, both clinicians and laboratory researchers, relating to the use and investigation of CTCs and CNAs. It covered current activities, recent developments and trends, three-year development plans (2014-2017), as well as new opportunities in diagnostics, research and drug R&D. Its findings provide integrated market information relevant to diagnostic companies, laboratory suppliers and drug developers, on the current and evolving use of CTCs and CNAs in these fields. Biopharm Reports carries out market studies of techniques and applications used in life science laboratories and clinics. All our studies involve the participation of scientists and clinicians and investigate in-depth, key areas of their current use of specialised laboratory techniques, and their plans for using these techniques over the next three years. Findings from these studies are based on 'real world' market data.


The current studies profiled more than 855 experienced clinicians and research scientists, including CTC and CNA current practices, developments, trends and three-year plans, as well as growth, shrinkage and opportunities across key areas of these two markets. Its findings provide suppliers with market information on the current and evolving use or CTCs and CNAs, and the techniques that are driving these developments.


Recent years have seen the rapid development of minimally invasive diagnostic techniques in the cancer field, notably so-called 'liquid biopsies', based on the detection and characterisation of Circulating Tumour Cells and Circulating (cell free) Nucleic Acids. Today, around 50 companies offer techniques that image, enrich, isolate and characterise CTCs and more advanced methods are also being used to isolate and characterise CNAs. Advances are also being seen in the study of CTC sub-populations, time-dependent changes and the markers used to isolate or enrich them and more advanced methods are increasingly being applied to CNAs. Both of these strategies are seeing rapid development, as researchers and developers seek to translate these methodologies and the findings they are providing, into tests that impact on clinical care or which drive new discovery. 

The isolation and characterisation of CTCs and CNAs are two of the fastest growing areas of research in the cancer field. Growth is also being seen in the translation of this research into diagnostic tests. Two new market studies by Biopharm Reports have profiled developments being seen in these fields. Market areas covered include growth, current and next three years; assays, test costs per patient, growth; CTC subpopulations, growth; isolation and detection, growth; suppliers, growth; cell markers, growth; molecular techniques, growth; molecular suppliers, growth; non-molecular techniques, growth; non-molecular suppliers, growth; companion diagnostics, growth; molecular forms, growth; biomarkers, growth; clinical utilities; limitations and purpose.

 

Circulating Tumour Cells (CTCs):

  • Current and 3-year CTC activities provided by 855 research scientists and clinicians
  • Growth in CTC tests and estimated growth over the next 3 years (±% change)
  • Cost estimates per sample, by scientists and clinicians, for patient CTC tests
  • CTC detection/enrichment platforms used currently and over next 3 years (±% change)
  • Company CTC platforms used currently and over the next 3 years (±% change)
  • Non-Molecular techniques used with CTCs, currently and in 3 years (±% change)
  • Suppliers of non-molecular techniques currently and anticipated in 3 years (±% change)
  • Molecular techniques used with CTCs, currently and anticipated in 3 years (±% change)
  • Suppliers of molecular techniques currently and anticipated in 3 years (±% change)
  • CTC markers studied currently and anticipated in 3 years (±% change)
  • CTC subpopulation studies currently, and anticipated in 3 years (±% change)
  • CTC subpopulation types studied currently and anticipated in 3 years (±% change)
  • Molecular forms studied currently and anticipated in 3 years (±% change)
  • Biomarkers studied currently and anticipated in 3 years (±% change)
  • Sample types studied currently for the purpose of CTC studies
  • Clinical utilities of CTCs in diagnostics currently and anticipated in 3 years (±% change)
  • Cancer types studied relating to the study of CTCs
  • Purpose of studies relating to CTCs
  • Limitations of current studies of CTCs
  • Fields or sectors
  • Global regions, countries and organisation types
  • CTC studies in drug R&D
  • Early-stage research of CTCs in drug R&D currently and in 3 years (±% change)
  • Pre-clinical research of CTCs in drug R&D currently and in 3 years (±% change)
  • Clinical research of CTCs in drug R&D currently and in 3 years (±% change)
  • CTC as clinical trials end-points currently and in 3 years (±% change)
  • CTCs as companion diagnostics in drug R&D currently and in 3 years (±% change)
  • Cancer types relating to CTCs in drug R&D, currently and in 3 years (±% change)

 

Free Circulating Nucleic Acids (CNAs):

 

  • Growth in CNA tests and estimated growth over the next 3 years (±% change)
  • Cost estimates per sample, by scientists and clinicians, for patient CNA tests
  • Molecular techniques used with CNAs, currently and anticipated in 3 years (±% change)
  • Suppliers of molecular techniques currently and anticipated in 3 years (±% change)
  • Molecular forms studied currently and anticipated in 3 years (±% change)
  • Biomarkers studied currently and anticipated in 3 years (±% change)
  • Sample types studied currently for the purpose of CNA studies
  • Clinical utilities of CNAs in diagnostics currently and anticipated in 3 years (±% change)
  • Cancer types studied relating to the study of CNAs
  • Purpose of studies relating to CNAs
  • Limitations of current studies of CNAs
  • Fields or sectors
  • Global regions, countries and organisation types
  • CNA studies in drug R&D
  • Early-stage research of CNAs in drug R&D currently and in 3 years (±% change)
  • Pre-clinical research of CNAs in drug R&D currently and in 3 years (±% change)
  • Clinical research of CNAs in drug R&D currently and in 3 years (±% change)
  • CNA as clinical trials end-points currently and in 3 years (±% change)
  • CNA parameters measured in drug R&D currently and in 3 years (±% change)
  • CNAs as companion diagnostics in drug R&D currently and in 3 years (±% change)
  • Cancer types relating to CNAs in drug R&D, currently and in 3 years (±% change)

 

Purchase or view full details of Circulating Tumor Cells (CTCs) & Free Circulating Nucleic Acids (FcNAs)

Request your free sample